Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Chemotherapy and Ovarian Function

Can GnRHa improve recovery rates in BC patients?

Given concurrently with chemotherapy to premenopausal patients undergoing treatment for early-stage breast cancer, gonadotropin-releasing hormone agonists (GnRHa) may be used to increase rates of recovery of regular menses and prevent early menopause, according to meta-analysis of 1,047 patients. The study determined:

• The use of GnRHa was associated with a higher rate of recover of regular menses after 6 months (OR=2.41) and at least 12 months (OR=1.85) following the last chemotherapy cycle.

• The use of GnRHa was associated with a higher number of pregnancies (OR=1.85).

• Evidence was insufficient to assess outcomes related to GnRHa and ovarian function and fertility.

Citation: Munhoz RR, Pereira AA, Sasse AD, et al. Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer. [Published online ahead of print October 1, 2015]. JAMA Oncol. doi: 10.1001/jamaoncol.2015.3251.